Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Subjects will be consented to the study prior to Coronary Artery Bypass Graft (CABG) and
randomly assigned to receive either ticagrelor 90 mg bid or placebo bid starting within 48
hours of surgery. Subjects will remain on study drug for a minimum of 12 months during which
time they will receive telephone follow-up one and nine months following CABG and clinic
visits three, six, and twelve months following CABG.